& Lee, Z-V
Humana offers D-SNPs in 34 states, adding two in CY 2023, and covers 0.7 million D-SNP beneficiaries (15% of D-SNP enrollment)
The embedded rings were cultured in Opti-Minimal Essential Medium (Thermo Fisher Scientific) supplemented with 2.5% fetal bovine serum, L-glutamate, 100 g/mL streptomycin, 100 U/mL penicillin, and 20 ng/mL VEGF (PeproTech, Cranbury, NJ, USA), and treated with lenvatinib (0.1 or 1 M) and/or L-carnitine (1.6, 6.4, or 25.6 mM) for 7 days
On further time-based analysis, we demonstrated a modest reduction in weight with GLP-1 RA use within the first 3 years (2.7% of baseline body weight) before rebounding to above baseline at 5 years
RuanBDongJWeiFHuangZYangBZhangLet al
If not, who decides our formulary?" Make the business case: Obesity treatment reduces long-term healthcare costs (diabetes, heart disease, joint problems) Gather support: If coworkers also want coverage, a group request carries more weight Time it right: Benefits are often reviewed in Q3-Q4 for the following year Be patient: Formulary changes typically take effect at the next plan year WHAT AETNA REQUIRES Prior Authorization Requirements Prior Authorization Requirements Wegovy Is Covered PA Is Required Since Wegovy is the preferred GLP-1 on most Aetna plans, the main hurdle is meeting the prior authorization requirements
